Autoimmune Diseases  >>  Kepivance (palifermin)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kepivance (palifermin) / SOBI, Amgen
CAM-THY, NCT01712945 / 2011-005606-30: Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis

Terminated
1/2
40
Europe
Palifermin, Kepivance, keratinocyte growth factor, Alemtuzumab, Campath-1H
Cambridge University Hospitals NHS Foundation Trust
Multiple Sclerosis
08/17
10/17

Download Options